论文部分内容阅读
目的探讨阿托伐他汀强化治疗急性冠状动脉综合征(急性冠脉综合征)患者经皮冠状动脉介入术(PCI)围手术期的效果。方法 162例急性冠脉综合征患者,随机分成观察组与对照组,每组81例。患者入院后均行PCI,对照组术前口服安慰剂,术后给予阿托伐他汀治疗;观察组在PCI术前12 h、术前2 h、术后口服阿托伐他汀。治疗后两组患者随访12个月,观察心血管事件发生率,监测肝肾功能,血、尿常规,随访完成后复查冠状动脉造影,比较靶血管支架内再狭窄率。结果两组患者均完成随访,观察组患者术后6个月心血管事件发生率、再狭窄率低于对照组,差异有统计学意义(P<0.05);两组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论急性冠脉综合征PCI围手术期强化阿托伐他汀治疗可明显降低患者12个月内心血管事件发生率及支架内再狭窄率。
Objective To investigate the perioperative effect of atorvastatin in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Methods 162 cases of acute coronary syndrome patients were randomly divided into observation group and control group with 81 cases in each group. The patients underwent PCI after admission. The control group was given placebo orally before surgery and atorvastatin was given to the patients in the control group. Atorvastatin was given 12 h before PCI and 2 h before PCI in the observation group. After treatment, the two groups of patients were followed up for 12 months. The incidence of cardiovascular events was observed. Liver and kidney function, blood and urine were monitored. Coronary angiography was performed after follow-up, and the rate of restenosis in target vessels was compared. Results Both groups were followed up. The incidence of cardiovascular events and the rate of restenosis at 6 months postoperatively in the observation group were significantly lower than those in the control group (P <0.05). The incidence of adverse reactions in both groups was significantly lower than that in the control group The difference was not statistically significant (P> 0.05). Conclusions Perioperative intensive atorvastatin treatment in patients with acute coronary syndrome can significantly reduce the incidence of cardiovascular events and the rate of in-stent restenosis within 12 months.